These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 1692094)

  • 1. Growth inhibition of murine melanoma and human colon carcinoma by recombinant human platelet factor 4.
    Sharpe RJ; Byers HR; Scott CF; Bauer SI; Maione TE
    J Natl Cancer Inst; 1990 May; 82(10):848-53. PubMed ID: 1692094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of tumor growth in mice by an analogue of platelet factor 4 that lacks affinity for heparin and retains potent angiostatic activity.
    Maione TE; Gray GS; Hunt AJ; Sharpe RJ
    Cancer Res; 1991 Apr; 51(8):2077-83. PubMed ID: 1706960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of development of murine melanoma lung metastases by systemic administration of recombinant platelet factor 4.
    Kolber DL; Knisely TL; Maione TE
    J Natl Cancer Inst; 1995 Feb; 87(4):304-9. PubMed ID: 7707422
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combination of Caspy2 and IP-10 gene therapy significantly improves therapeutic efficacy against murine malignant neoplasm growth and metastasis.
    Zhang N; Yang Y; Cheng L; Zhang XM; Zhang S; Wang W; Liu SY; Wang SY; Wang RB; Xu WJ; Dai L; Yan N; Fan P; Dai LX; Tian HW; Liu L; Deng HX
    Hum Gene Ther; 2012 Aug; 23(8):837-46. PubMed ID: 22548488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The COOH-terminal peptide of platelet factor-4 variant (CXCL4L1/PF-4var47-70) strongly inhibits angiogenesis and suppresses B16 melanoma growth in vivo.
    Vandercappellen J; Liekens S; Bronckaers A; Noppen S; Ronsse I; Dillen C; Belleri M; Mitola S; Proost P; Presta M; Struyf S; Van Damme J
    Mol Cancer Res; 2010 Mar; 8(3):322-34. PubMed ID: 20215425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antitumor effect of recombinant human interleukin 1 alpha against murine syngeneic tumors.
    Nakamura S; Nakata K; Kashimoto S; Yoshida H; Yamada M
    Jpn J Cancer Res; 1986 Aug; 77(8):767-73. PubMed ID: 3093425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Liposomal glucocorticoids as tumor-targeted anti-angiogenic nanomedicine in B16 melanoma-bearing mice.
    Banciu M; Metselaar JM; Schiffelers RM; Storm G
    J Steroid Biochem Mol Biol; 2008 Jul; 111(1-2):101-10. PubMed ID: 18602825
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Failure of thalidomide to inhibit tumor growth and angiogenesis in vivo.
    Gutman M; Szold A; Ravid A; Lazauskas T; Merimsky O; Klausner JM
    Anticancer Res; 1996; 16(6B):3673-7. PubMed ID: 9042240
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Aerosol delivery of PEI-p53 complexes inhibits B16-F10 lung metastases through regulation of angiogenesis.
    Gautam A; Densmore CL; Melton S; Golunski E; Waldrep JC
    Cancer Gene Ther; 2002 Jan; 9(1):28-36. PubMed ID: 11916242
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mouse macrophage metalloelastase gene transfer into a murine melanoma suppresses primary tumor growth by halting angiogenesis.
    Gorrin-Rivas MJ; Arii S; Furutani M; Mizumoto M; Mori A; Hanaki K; Maeda M; Furuyama H; Kondo Y; Imamura M
    Clin Cancer Res; 2000 May; 6(5):1647-54. PubMed ID: 10815882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antivascular endothelial growth factor receptor (fetal liver kinase 1) monoclonal antibody inhibits tumor angiogenesis and growth of several mouse and human tumors.
    Prewett M; Huber J; Li Y; Santiago A; O'Connor W; King K; Overholser J; Hooper A; Pytowski B; Witte L; Bohlen P; Hicklin DJ
    Cancer Res; 1999 Oct; 59(20):5209-18. PubMed ID: 10537299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mouse dendritic-endothelial cell hybrids and 4-1BB costimulation elicit antitumor effects mediated by broad antiangiogenic immunity.
    Ko E; Luo W; Peng L; Wang X; Ferrone S
    Cancer Res; 2007 Aug; 67(16):7875-84. PubMed ID: 17699794
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Synergy between an antiangiogenic integrin alphav antagonist and an antibody-cytokine fusion protein eradicates spontaneous tumor metastases.
    Lode HN; Moehler T; Xiang R; Jonczyk A; Gillies SD; Cheresh DA; Reisfeld RA
    Proc Natl Acad Sci U S A; 1999 Feb; 96(4):1591-6. PubMed ID: 9990069
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of angiogenesis by recombinant human platelet factor-4 and related peptides.
    Maione TE; Gray GS; Petro J; Hunt AJ; Donner AL; Bauer SI; Carson HF; Sharpe RJ
    Science; 1990 Jan; 247(4938):77-9. PubMed ID: 1688470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant human fibronectin polypeptide CH50 on growth and metastasis of melanoma.
    Fan Q; Feng ZH; Zhang GM; Zhang H; Cao HQ
    Zhongguo Yao Li Xue Bao; 1999 Feb; 20(2):175-8. PubMed ID: 10437168
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of a B16-F10 melanoma model locally implanted into the ear pinnae of C57BL/6 mice.
    Potez M; Trappetti V; Bouchet A; Fernandez-Palomo C; Güç E; Kilarski WW; Hlushchuk R; Laissue J; Djonov V
    PLoS One; 2018; 13(11):e0206693. PubMed ID: 30395629
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of U-995, a potent shark cartilage-derived angiogenesis inhibitor, on anti-angiogenesis and anti-tumor activities.
    Sheu JR; Fu CC; Tsai ML; Chung WJ
    Anticancer Res; 1998; 18(6A):4435-41. PubMed ID: 9891506
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor cells engineered to express interleukin-6 exhibit a reduced tumorigenicity depending on the tumor cell model.
    Ledda MF; Adris S; Bravo AI; Bover L; Carbone C; Paleolog E; Mordoh J; Chernajovsky Y; Podhajcer OL
    Cell Mol Biol (Noisy-le-grand); 1996 Jul; 42(5):769-78. PubMed ID: 8832108
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Thrombospondin-1 type 1 repeat recombinant proteins inhibit tumor growth through transforming growth factor-beta-dependent and -independent mechanisms.
    Miao WM; Seng WL; Duquette M; Lawler P; Laus C; Lawler J
    Cancer Res; 2001 Nov; 61(21):7830-9. PubMed ID: 11691800
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blocking angiogenesis and tumorigenesis with GFA-116, a synthetic molecule that inhibits binding of vascular endothelial growth factor to its receptor.
    Sun J; Blaskovich MA; Jain RK; Delarue F; Paris D; Brem S; Wotoczek-Obadia M; Lin Q; Coppola D; Choi K; Mullan M; Hamilton AD; Sebti SM
    Cancer Res; 2004 May; 64(10):3586-92. PubMed ID: 15150116
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.